Early research (Phase 1)Study completedNCT02286817
What this trial is testing
Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity Disorder
Who this might be right for
Attention-deficit Hyperactivity Disorder (ADHD)
Aevi Genomic Medicine, LLC, a Cerecor company 30